eSampling vs Physical Samples: Cost and Conversion Comparison

Product sampling remains one of the most widely used tactics in pharmaceutical marketing, with the industry distributing approximately $6-8 billion worth of product samples annually in the United States alone. The fundamental premise is straightforward: give physicians the opportunity to try your product with a patient, and a percentage of those trial experiences will convert into ongoing prescriptions. Yet the way samples are delivered has undergone a dramatic shift over the past five years, with electronic sampling (eSampling) platforms capturing an increasing share of sample volume.

This article provides a comprehensive, data-driven comparison of eSampling and traditional physical sampling across cost, conversion, compliance, and operational dimensions to help brand teams make informed allocation decisions.

Cost Comparison: The Full Cost per Sample

When comparing the cost of eSampling versus physical samples, it is critical to account for the full cost per sample, not just the cost of goods. Physical samples carry a complex cost structure that includes manufacturing, packaging, storage, shipping, rep carry time, and waste from expired or damaged units. eSampling eliminates many of these costs but introduces technology platform fees, digital fulfillment costs, and integration expenses.

The cost advantage of eSampling varies by product type. For small-molecule oral medications with low cost of goods, the non-product cost components are a larger percentage of total cost, making the eSampling savings more impactful. For high-cost biologics and specialty injectables, the product cost of goods dominates, and the delivery method savings are proportionally smaller.

Conversion Rate Comparison

Cost per sample is only half the equation. The real question is which method produces higher conversion rates: a higher percentage of samples resulting in new-to-brand prescriptions. The conversion rate data is nuanced and depends heavily on the therapeutic area, the product type, and the HCP specialty.

Several patterns emerge from the conversion data. For primary care and specialty oral medications, eSampling often matches or slightly outperforms physical sampling because the convenience of electronic ordering lowers the barrier to request a sample, and the automated follow-up sequences that eSampling platforms provide increase the likelihood that the physician will actually dispense the sample to a patient and track the outcome.

However, for oncology, rare disease, and complex injectable products, physical samples still outperform electronic alternatives. These therapeutic areas involve high-acuity patients where physicians prefer to have the physical product on hand in the clinic, and the in-person rep interaction that accompanies a physical sample delivery adds clinical context that supports the trial decision.

The hybrid approach, which combines electronic request capability with strategic physical sample placement, consistently outperforms either method alone. This suggests that the optimal strategy is not choosing one channel over the other but rather integrating both into a coordinated sampling program.

HCP Preference Data

Physician preferences for sample delivery method have shifted significantly over the past five years. A 2025 survey of 1,200 HCPs across specialties found that 58% now prefer eSampling as their primary method for ordering samples, up from 34% in 2021. The preference shift is driven by convenience (ordering samples from any device at any time), reduced clutter (no physical inventory to manage), better tracking (automated documentation for compliance), and pandemic-era habit changes that accelerated digital adoption.

• Primary care physicians: 65% prefer eSampling, citing convenience and reduced office clutter as primary reasons.
• Specialists (non-oncology): 55% prefer eSampling, with higher preference among younger physicians (under 45).
• Oncologists: 40% prefer eSampling, with 45% preferring physical samples and 15% neutral. The complexity of oncology treatment protocols and the need for immediate access drive the physical preference.
• Nurse practitioners and PAs: 62% prefer eSampling, valuing the convenience and the reduced administrative burden.

Compliance and Tracking

Compliance with the Prescription Drug Marketing Act (PDMA) and state sampling regulations is a critical consideration. Both physical and electronic sampling must comply with PDMA requirements for tracking, reporting, and accountability, but the ease of compliance varies significantly between methods.

eSampling platforms provide built-in PDMA compliance through digital signatures, automated tracking of sample receipt and acknowledgment, real-time inventory management, and automated reporting for state aggregate spend and sample distribution reporting. Physical samples require manual tracking through Veeva CRM or similar systems, with rep-entered data that is subject to errors and delays. Audit findings consistently show that physical sample tracking has error rates of 5-12%, compared to less than 1% for electronic platforms.

Platform Options

The eSampling platform landscape has matured significantly, with several established vendors offering integrated solutions that connect to Veeva CRM, major wholesale distributors (McKesson, Cardinal, AmerisourceBergen), and specialty pharmacies. Key platforms include Veeva CRM Samples, TrialCard, OPTIMIZERx, and DirectRX. Selection criteria should include CRM integration depth, distributor connectivity, HCP authentication methods, compliance features, analytics and reporting capabilities, and cost structure.

Optimal Allocation Strategy

Based on the cost, conversion, compliance, and preference data, the optimal sampling allocation for most brands is a hybrid model that uses eSampling as the primary channel for routine sample distribution and physical samples strategically for high-value HCPs, complex products, and situations where the rep interaction adds clinical value.

The shift toward eSampling is accelerating, and brands that have not yet implemented electronic sampling capabilities should prioritize doing so. The cost savings, compliance improvements, and HCP preference trends all favor a greater role for electronic distribution. However, the data also shows that physical samples remain superior for complex products and high-acuity therapeutic areas. The winning strategy is not either-or but a coordinated hybrid that leverages the strengths of both channels.